Global Peptide Therapeutics Market & Pipeline Insight

  • ID: 2763936
  • Drug Pipelines
  • Region: Global
  • 1350 Pages
  • PNS Pharma
1 of 4
With a very significant role in modulating cell functions, peptides are used in many physiological and pathological processes. The peptide drugs are of late being increasingly used in treatment of certain specific human diseases, which has increased the demand in this market.

Previously peptide drugs were not very popular. However, in recent years, as the total number of small molecule-based drugs in the clinical trials and approved drugs for the market is decreasing rapidly, the pharma companies along with the academia are increasingly paying more attention to peptides or other bioactive drugs. At present, in the global market, there are close to 90 approved peptide drugs, with 278 more in clinical trials and 319 additional ones in the pre-clinical studies.

There are many applications of the peptide drugs. The most popular and dominant segments include cancer peptide segment, which accounted for the largest share of more than 20%. It is most likely that due to rising incidence of cancer across the globe, this application market is expected to record a strong growth in the future. The second significant segment of peptide drugs is the neuropeptides application segment, which is expected to record a growth rate of more than 9-10% through 2018 owing to an increasing number of neurological disorders such as Alzheimer's and Parkinson's disease across the globe.

With significant advancements in genomics which have identified new targets for peptide drugs and a rising popularity and awareness among the patients about the better safety levels than small molecule drugs, the global market for peptide therapeutics was estimated to be close to USD 17 billion in 2013. With factors such as rising incidence of cardiovascular diseases, metabolic diseases and advances in technology actively pushing the demand for peptide drugs, this market is expected to grow at a CAGR of 9-10% to reach approximately USD 27.3 billion by 2018.

“Global Peptide Therapeutics Market & Pipeline Insight” Report Highlights & Key Findings:

- Global Peptides Drug Market Overview
- Peptides Pipeline by Phase, Indication & Country
- Peptide Pipeline by Peptide Class
- Competitive Landscape
- Peptides in Development Phase: 597
- Marketed Peptides: 90
- Maximum Number of Peptides in Preclinical Phase: 253
- Maximum Number of Peptides Belongs To: Peptides/ Peptide Hormones/ Peptide Fragments
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Global Peptide Market Outlook
1.1 Introduction to Peptides
1.2 Market Overview
1.3 Regional Market Analysis
1.4 Market Drivers
1.5 Issues to be Addressed
1.6 Peptide Clinical Pipeline Analysis

2. Peptides/ Peptide Hormones/ Peptide Fragments Pipeline by Phase, Indication & Country
2.1 Research till Preregistration
2.2 Marketed

3. Cyclic Peptides Pipeline by Phase, Indication & Country
3.1 Research till Preregistration
3.2 Marketed

4. Depsi Peptides Pipeline by Phase, Indication & Country
4.1 Research till Preregistration
4.2 Marketed

5. Dipeptides Pipeline by Phase, Indication & Country
5.1 Research till Preregistration
5.2 Marketed

6. Glyco Peptides Pipeline by Phase, Indication & Country
6.1 Research till Preregistration
6.2 Marketed

7. Lipo Peptides Pipeline by Phase, Indication & Country
7.1 Research till Preregistration

8. Neuro Peptides Pipeline by Phase, Indication & Country
8.1 Preregistration
8.2 Marketed

9. Natriuretic Peptides Pipeline by Phase, Indication & Country
9.1 Research till Preregistration
9.2 Marketed

10. Oligo Peptides Pipeline by Phase, Indication & Country
10.1 Research till Preregistration
10.2 Marketed

11. Opioid Peptides Pipeline by Phase, Indication & Country
11.1 Research till Preregistration

12. Competive Landscape
12.1 Amgen
12.2 Amylin Pharmaceuticals
12.3 Corden Pharma (Peptisyntha)
12.4 GlaxoSmithKline
12.5 Ipsen
12.6 Lonza Inc.
12.7 Roche
12.8 PeptiDream
12.9 Merck & Co
12.10 Sanofi

Figure 1-1: Global Peptide Market (US$ Billion), 2013-2018
Figure 1-2: Global Peptide Pipeline by Peptide Type, 2014
Figure 1-3: Global Peptide Pipeline by Clinical Phase, 2014
Figure 1-4: Peptide Hormones/ Peptide Fragments Pipeline by Clinical Phase, 2014
Figure 1-5: Glycopeptides Pipeline by Clinical Phase, 2014
Figure 1-6: Lipopeptides Pipeline by Clinical Phase, 2014
Figure 1-7: Oligopeptides Pipeline by Clinical Phase, 2014
Figure 1-8: Depsipeptides Pipeline by Clinical Phase, 2014
Figure 1-9: Neuropeptides Pipeline by Clinical Phase, 2014
Figure 1-10: Dipeptides Pipeline by Clinical Phase, 2014
Figure 1-11: Cyclicpeptides Pipeline by Clinical Phase, 2014
Figure 1-12: Natriureticpeptides Pipeline by Clinical Phase, 2014
Figure 1-13: Opioidpeptides Pipeline by Clinical Phase, 2014
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll